HER2 Key Differences and Current Approaches to Biomarker Testing
Panelist discusses how HER2 testing evaluates protein overexpression, gene amplification, and mutations. Although breast and gastric cancers typically show overexpression/amplification, other tumors more commonly harbor mutations.
Video content above is prompted by the following:
- What are the key differences between HER2 overexpression, amplification, and mutations across tumor types? How do these differences affect treatment selection?
- What is your current approach to biomarker testing for HER2 alterations across different tumor types?
Recent Videos
Related Content
Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies
June 13th 2024Article
"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."
